Literature DB >> 6300372

Hepatotoxic effects of estradiol-17 beta-D-glucuronide in the rat and monkey.

W Slikker, M Vore, J R Bailey, M Meyers, C Montgomery.   

Abstract

The steroid D-ring glucuronide conjugate estradiol-17 beta-D-glucuronide (E217G) but not the A-ring conjugate E23-glucuronide (E23G) has been shown to inhibit bile flow in the rat. To determine if primates are also sensitive to E217G-induced cholestasis, a noninvasive approach with the use of indocyanine green (ICG), a dye eliminated primarily by biliary excretion, was first validated in the rat and then applied to the rhesus monkey. ICG (16 mg/kg rat; 4 mg/kg monkey) was administered i.v. 10 min after an i.v. bolus dose of either E217G (5.5 or 11 mumol/kg), E23G (11 mumol/kg) or vehicle alone. In the rat, the elimination T1/2 of ICG was increased by the 11 mumol/kg dose of E217G (P less than .025), whereas E23G produced no significant change from vehicle control values. In the monkey, the 5.5 and 11 mumol/kg doses of E217G increased the T1/2 of ICG in a dose-related manner (P less than .005), whereas E23G was without effect. Plasma levels of total radioactivity demonstrated dose-dependent kinetics after the administration of a tracer dose and 11 mumol/kg of [3H]E217G. A rebound of plasma radioactivity was seen at 11 mumol/kg of [3H] E217G, the time course of which mimicked the time course of E217G-induced cholestasis. High-performance liquid chromatographic analysis of rat bile and plasma after the administration of [3H]E217G revealed primarily E217G and estradiol-3-sulfate-17 beta-D-glucuronide together with small amounts of three unidentified metabolites. In the monkey, only E217G and estradiol-3-sulfate-17 beta-D-glucuronide were observed in the plasma after the administration of [3H]E217G. In contrast to E217G, estradiol-3-sulfate-17 beta-D-glucuronide was choleretic in the bile duct-cannulated rat model. These data indicate that E217G is hepatotoxic in both rodents and nonhuman primates.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6300372

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Mechanistic Modeling of the Hepatic Disposition of Estradiol-17β-Glucuronide in Sandwich-Cultured Human Hepatocytes.

Authors:  Katsuaki Ito; Noora Sjöstedt; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2019-11-19       Impact factor: 3.922

Review 2.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

Review 3.  Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation.

Authors:  B Burchell; M W Coughtrie
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

4.  Detection of postoperative granulation tissue with an ICG-enhanced integrated OI-/X-ray System.

Authors:  Reinhard Meier; Sophie Boddington; Christian Krug; Frank L Acosta; Daniel Thullier; Tobias D Henning; Elizabeth J Sutton; Sidhartha Tavri; Jeffrey C Lotz; Heike E Daldrup-Link
Journal:  J Transl Med       Date:  2008-11-27       Impact factor: 5.531

5.  Novel testing strategy for prediction of rat biliary excretion of intravenously administered estradiol-17β glucuronide.

Authors:  Annelies Noorlander; Eric Fabian; Bennard van Ravenzwaay; Ivonne M C M Rietjens
Journal:  Arch Toxicol       Date:  2020-11-07       Impact factor: 5.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.